Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …

A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …

Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …

Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ
systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in …

Objective To determine the prognostic value of pulmonary function test (PFT) trends at 1 and
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …

Objective To assess survival and incidence of organ‐based complications in a large single‐
center cohort of unselected systemic sclerosis (SSc) patients, and to explore predictors of …

Systemic sclerosis is a complex autoimmune disease characterized by a chronic and
frequently progressive course and by extensive patient-to-patient variability. Like other …

Rationale: Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis
(SSc), but there are no precise, population-based data on its overall impact, limiting …

Multisystem autoimmune rheumatic diseases are heterogeneous rare disorders associated
with substantial morbidity and mortality. Efforts to create international consensus within the …

Pulmonary complications are an important extra-articular feature of autoimmune rheumatic
diseases and a major cause of mortality. The underlying pathogenesis probably involves …